Cox Enzyme
Cox Enzyme - Related Videos
10:26
Imaging Neurons within Thick Brain Sections Using the Golgi-Cox Method
0 Views •
Cited by 10 •
2017
We present a protocol for using the Golgi-Cox staining method in thick brain sections, in order to visualize neurons with long dendritic trees contained within single tissue samples. Two variants of this protocol are also presented that involve cresyl violet counterstaining, and the freezing of unprocessed brains for long-term storage.
06:53
Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry
0 Views •
Cited by 82 •
2011
The cytochrome c oxidase/sodium dehydrogenase (COX/SDH) double-labeling method allows for direct visualization of mitochondrial respiratory enzyme deficiencies in fresh-frozen tissue sections. This is a straightforward histochemical technique and is useful in investigating mitochondrial diseases, aging, and aging-related disorders.
02:37
Microscopic Imaging of Neurons in a Mouse Brain Section Using Golgi-Cox Metallic Staining
0 Views •
2025
Source: Louth, E. L., et al. Imaging neurons within thick brain sections using the Golgi-Cox method. J. Vis. Exp. (2017)This video demonstrates imaging neurons in a Golgi-Cox stained thick brain section by setting upper and lower focus boundaries and capturing overlapping images. Multiple locations are imaged to ensure detailed neuronal projections, which are combined to create a 3D representation.
02:34
Enzymes
0 Views •
2020
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions. Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
01:19
The Mantel-Cox Log-Rank Test
0 Views •
2025
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of interest.
FAQs
Prostaglandin H2 is the central intermediate formed when arachidonic acid is processed by Cox enzymes. It serves as the precursor for several signaling molecules, including prostaglandins, prostacyclin, and thromboxanes. Consequently, reducing Cox activity decreases production across these downstream pathways, helping explain why Cox inhibition can influence pain, fever, inflammation, platelet function, and vascular or renal processes.
Their pharmacological importance reflects when and where they contribute to mediator production. COX-1 supports functions present under ordinary physiological conditions, including gastric protection, platelet activity, and renal regulation. COX-2 is commonly increased by inflammatory signals and contributes to pain, fever, and swelling. This distinction guides attempts to suppress inflammation while limiting interference with protective functions.
COX-2-selective inhibition focuses more directly on the enzyme associated with inflammatory signaling, whereas nonselective inhibition affects both COX-1 and COX-2 activity. Because COX-1 supports gastric protection and platelet function, broader inhibition can increase gastrointestinal concerns. Comparisons must also consider potential cardiovascular effects associated with COX-2-directed pharmacology, rather than judging selectivity only by anti-inflammatory benefit.
NSAIDs reduce Cox activity, limiting formation of prostaglandin H2 and the downstream prostaglandins derived from it. Lower prostaglandin production accounts for the principal therapeutic outcomes associated with this drug class: decreased pain, reduced fever, and diminished inflammation. The same pathway-based mechanism also explains why pharmacological benefit must be evaluated alongside effects on physiological processes supported by Cox products.
The comparison examines which Cox isoforms a drug inhibits and then relates that selectivity to therapeutic effects and risks. Nonselective inhibitors are evaluated for their effects on both inflammatory and ordinary physiological pathways, while COX-2-selective inhibitors are assessed for targeted inflammatory control, gastrointestinal considerations, and potential cardiovascular effects. This framework supports balanced interpretation of efficacy and safety.
Assessment should include the intended reduction in pain, fever, or swelling, together with consequences for gastric protection, platelet function, renal regulation, and cardiovascular safety. Pharmacologists can also determine whether an intervention acts broadly or preferentially on COX-1 and COX-2. Considering therapeutic and physiological outcomes together clarifies the practical significance of changing prostaglandin production.